AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) announced that top-line data from its previously announced open-label, active-comparator study of its lead product ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE